This study looks at whether the drug nilotinib can help people with chronic myeloid leukemia (CML) stay in remission after stopping their usual treatment for a second or third time. About 75 adults who previously tried and failed to stop TKI therapy will take nilotinib for at lea…
Phase: PHASE2 • Sponsor: European LeukemiaNet • Aim: Disease control
Last updated May 17, 2026 10:45 UTC